半乳糖凝集素3与心力衰竭心室重构关系的研究进展  

The research development of Galectin-3 in cardiac remodeling for heart failure

作　　者：金朦超 魏思琪 高蓉蓉[1] 李新立[1] 

机构地区：[1]南京医科大学第一附属医院心内科,南京210029

出　　处：《临床心血管病杂志》2016年第5期441-445,共5页Journal of Clinical Cardiology

基　　金：国家"十二五"科技支撑计划项目(No:2011BAI11B08)

摘　　要：心室重构在心力衰竭发生发展病理过程中具有重要作用。半乳糖凝集素3(Gal-3)作为心力衰竭新的生物标志物之一,不但参与肺、肝脏、肾脏和血管的纤维化过程,在心力衰竭心室重构过程中亦占据着不容忽视的地位。其通过参与心肌纤维化及炎症反应等引起心肌改变,针对其抑制剂的相关研究具有重要意义。本文综述Gal-3与心力衰竭心室重构相关的试验进展。The effects of cardiac remodeling on heart failure have been recognized gradually.Galectin-3,as a novel biomarker for heart failure,not only plays a role in the development of fibrosis in lung,liver,kidney and blood vessels,but also in cardiac remodeling.Involving in fibrosis and inflammatory response,Galectin-3makes myocardial pathological changes.Studies focusingon anti-galectin-3 therapyin treating heart failure may be helpful to the patients.This review summarizes the research development of Galectin-3in cardiac remodeling for heart failure.

关 键 词：半乳糖凝集素3 心力衰竭 心室重构 纤维化 抑制剂 

分 类 号：R541.6[医药卫生—心血管疾病]